Amarin Corp. (Nasdaq: AMRN) announced a $100 million non-equity financing through Pharmakon Advisors and detailed plans to commercialize its high cholesterol medication Vascepa in-house rather than through a partnership. The stock price plummeted $2.25 to $9.70.